Equities

CanBas Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4575:TYO

CanBas Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)868.00
  • Today's Change-14.00 / -1.59%
  • Shares traded251.80k
  • 1 Year change-16.86%
  • Beta-2.3409
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CanBas Co Ltd is a Japan-based company mainly engaged in drug development and research. The company is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-1.25bn
  • Incorporated2000
  • Employees14.00
  • Location
    CanBas Co Ltd2-2-1, Ote-machiNUMAZU-SHI 410-0801JapanJPN
  • Phone+81 559543666
  • Fax+81 559543668
  • Websitehttps://www.canbas.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wakamoto Pharmaceutical Co Ltd9.29bn298.60m11.11bn286.0037.080.915715.001.208.608.60267.77348.390.60061.623.0632,493,160.001.93-0.06782.22-0.078147.7048.653.21-0.12462.42--0.0082--0.6595-6.53-40.86--21.87--
Stella Pharma Corp968.76m-279.32m12.66bn43.00--4.70--13.07-8.21-8.2128.4779.220.19660.09442.9122,529,260.00-5.67-16.41-5.96-18.1987.8887.03-28.83-176.1613.81-45.690.226--256.62--81.56---21.34--
CellSeed Inc83.68m-1.10bn13.31bn38.00--10.09--159.04-31.83-31.832.4135.670.04090.65613.81---54.00-46.88-59.08-50.9551.0953.64-1,319.46-593.855.81--0.0949---56.71-15.95-28.41--21.04--
Immuno-Biological Laboratories Co., Ltd.1.03bn363.89m15.14bn58.0041.598.5939.5914.6739.0739.07110.76189.250.54560.86034.8117,786,030.0019.25-4.9622.46-5.7770.3562.7035.27-11.273.962,702.080.0947--18.7110.9533.40------
ReproCell Inc2.52bn-324.61m15.45bn99.00--1.76--6.13-3.42-3.4226.6392.820.23284.155.9225,450,770.00-3.00-4.09-3.63-4.4749.3543.75-12.88-13.664.93--0.00--22.7419.94428.65---6.31--
TAIKO PHARMACEUTICAL CO LTD6.40bn923.00m15.60bn214.0016.761.8213.122.4418.3718.37127.34169.510.50801.772.62--7.34-18.999.32-24.0454.4240.2014.44-46.312.72--0.0874--1.67--2.78------
CanBas Co Ltd (Parent)0.00-1.25bn17.39bn14.00--7.31-----64.11-64.110.00120.620.00----0.00-44.48-57.04-46.19-62.13-------4,587.85---566.180.00------4.27------
StemRIM Inc0.00-1.90bn18.62bn45.00--2.71-----30.56-30.560.00109.730.00----0.00-24.08-12.71-24.55-12.88-------167.3547.00--0.00------4.59---22.11--
Ohki Healthcare Holdings Co Ltd359.41bn2.43bn19.01bn648.007.570.55466.720.0529178.43178.4326,346.692,435.832.269.834.34554,637,400.001.531.776.237.745.315.260.6770.69770.8306--0.268614.174.424.7419.412.2145.686.47
Astena Holdings Co Ltd62.74bn2.19bn19.97bn1.42k8.960.72394.340.318354.2254.221,555.72671.410.89613.622.88--3.110.95876.261.7634.8530.403.471.050.9228--0.4519114.258.19-0.808186.601.9712.612.38
Kubota Pharmaceutical Holdings Co Ltd21.34m-676.25m20.31bn19.00--11.20--952.01-10.91-10.910.334115.720.01213.547.98---38.41-44.81-42.10-49.35-14.68---3,169.69-8,411.5912.49--0.0121---21.53-10.8049.26---4.55--
Fuso Pharmaceutical Industries Ltd62.17bn-4.01bn22.43bn1.34k--0.5846--0.3608-469.00-469.007,280.214,059.080.73073.252.3246,394,780.00-4.710.7682-9.761.2926.3926.94-6.441.050.822869.880.4617106.299.315.25-338.78--4.376.45
Renascience Inc106.94m-258.99m24.18bn3.00--9.81--226.11-20.35-20.358.40186.090.0479--4.8635,648,000.00-11.59-8.97-12.40-9.3595.9484.44-242.17-107.53----0.00---31.6613.00143.91------
Data as of Feb 17 2026. Currency figures normalised to CanBas Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.74%Per cent of shares held by top holders
HolderShares% Held
Long Corridor Asset Management Ltd.as of 08 Nov 2024292.70k1.49%
Simplex Asset Management Co., Ltd.as of 05 Feb 202649.70k0.25%
Data from 31 Dec 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.